Vident Investment Advisory, LLC Uni Qure N.V. Transaction History

Vident Investment Advisory, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $54 - $81	-3 Reduced -0.0%	75,219 $1.71 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $1.28 Million - $1.92 Million	75,222 New	75,222 $1.41 Million
Q3 2021 Nov 12, 2021	SELL	$26.01 - $38.22 $183,266 - $269,298	-7,046 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$29.97 - $37.17 $211,168 - $261,899	7,046 New	7,046 $217,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.